CSIMarket
 
Tengjun Biotechnology Corp   (CHGH)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 100
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 0

Tengjun Biotechnology Corp
Tengjun Biotechnology Corp is a biotechnology company focused on the development and commercialization of innovative healthcare solutions. They specialize in the research, manufacturing, and distribution of high-quality biopharmaceuticals and medical devices. With a strong emphasis on cutting-edge technology and scientific expertise, Tengjun Biotechnology Corp aims to address unmet medical needs and improve patient outcomes. They have a diverse portfolio of products ranging from novel drug candidates to advanced diagnostic tools.


   Company Address: East Jinze Road and South Huimin Road Jining City 0
   Company Phone Number: 0537-8711599   Stock Exchange / Ticker: CHGH
   CHGH is expected to report next financial results on April 16, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Tengjun Biotechnology Corp

Tengjun Biotechnology Corp delivers staggering revenue results, surpassing last year's figures in the second quarter of 2023 earnings season



As the second quarter of 2023 earnings season comes to a close, investors have received a mixed bag of results from CHGH and Tengjun Biotechnology Corp. While both companies have experienced significant changes compared to the same reporting season a year ago, the overall performance raises questions about their future direction.
CHGH, while achieving balanced books with $0.00 per share, has seen a decline from $0.06 per share in the previous year. Revenue remained stagnant at $0.00 million, down from $51.29 million in the same reporting season a year earlier and $8.52 million sequentially. This lack of revenue growth indicates the need for CHGH to explore strategies that can reignite growth and increase shareholder value.

Tengjun Biotechnology Corp

Tengjun Biotechnology Corp Demonstrates Mixed Financial Results, Reports Revenue Surge of 98.796% in Q1 of 2023 Earnings Season

Tengjun Biotechnology Corp, a company engaged in the research, development, and production of bioactive peptides, showed mixed financial results for the fiscal span closing March 31, 2023. The company reported earnings of $0.00 per share, down from $65,309,169.00 a year prior, and from $0.02 per share from the previous reporting season. However, the company's revenue rose by 98.796% to $8.52 million from $4.28 million in the same reporting season a year before. Sequentially, revenue tumbled by -85.353% from $58.14 million.
Although the company reported a decline in net profits to $0.391 million, down by -31.78% from 0 in the corresponding period a year before, the company's operating earnings increased by 76.82% to $0.575986 million. It appears that Tengjun Biotechnology Corp shifted its focus on improving sales, which resulted in a net margin of 4.59%.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com